Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313891 | 0.85 | DPP4 (0.38) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL17913615 | 0.80 | — | — | |
| SCHEMBL9661620 | 0.80 | LMNA (0.34) | DPP4ALOX15 | |
| SCHEMBL9660192 | 0.77 | S1PR1 (0.41) | DPP4 | |
| SCHEMBL499972 | 0.76 | S1PR1 (0.47) | DPP4 | |
| SCHEMBL499973 | 0.76 | S1PR1 (0.47) | DPP4 | |
| SCHEMBL4630950 | 0.75 | — | — | |
| SCHEMBL9660545 | 0.75 | — | — | |
| SCHEMBL2089853 | 0.74 | KCNK3 (0.38) | DPP4 | |
| SCHEMBL9660792 | 0.74 | S1PR1 (0.49) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080038349-A1 | Peptide-Pna Chimera Targeting Inducible Nitric Oxide Synthetase | ITSCHAK LAMENSDORF | 2008-02-14 | — | — | US | claimed |
| EP-1680438-A2 | AMIPHIPHYLIC PEPTIDE-PNA CONJUGATES FOR THE DELIVERY OF PNA THROUGH THE BLOOD BRAIN BARRIER | Kernel Biopharma Inc. (IL) | 2006-07-19 | — | — | EP | claimed |
| EP-1680439-A2 | DUAL PHASE-PNA CONJUGATES FOR THE DELIVERY OF PNA THROUGH THE BLOOD BRAIN BARRIER | Kernel Biopharma Inc. (IL) | 2006-07-19 | — | — | EP | claimed |
| US-20060142227-A1 | Amphiphylic peptide-PNA conjugates for the delivery of PNA through the blood brain barrier | LAMENSDORF ITSCHAK | 2006-06-29 | — | — | US | claimed |
| US-20050222009-A1 | Dual phase - PNA conjugates for the delivery of PNA through the blood brain barrier | LAMENSDORF ITSCHAK | 2005-10-06 | — | — | US | claimed |
| WO-2005076732-A2 | PEPTIDE-PNA CHIMERA TARGETING INDUCIBLE NITRIC OXIDE SYNTHASE | KERNEL BIOPHARMA INC. (IL) | 2005-08-25 | — | — | WO | claimed |
| WO-2005035550-A2 | DUAL PHASE-PNA CONJUGATES FOR THE DELIVERY OF PNA THROUGH THE BLOOD BRAIN BARRIER | KERNEL BIOPHARMA INC. (IL) | 2005-04-21 | — | — | WO | claimed |
| WO-2005035549-A2 | AMIPHIPHYLIC PEPTIDE-PNA CONJUGATES FOR THE DELIVERY OF PNA THROUGH THE BLOOD BRAIN BARRIER | KERNEL BIOPHARMA INC. (IL) | 2005-04-21 | — | — | WO | claimed |
| US-20040063906-A1 | Peptide nucleic acid sequences; antibodies for controlling disease; bactericides, viricides | NIELSEN PETER E (DK) | 2004-04-01 | — | — | US | claimed |
| EP-1335933-A2 | PNA ANALOGUES | Pantheco A/S (DK) | 2003-08-20 | — | — | EP | claimed |
| WO-2002042316-A2 | PNA ANALOGUES | PANTHECO A/S (DK) | 2002-05-30 | — | — | WO | claimed |
| US-7479536-B1 | Chiral, charged peptide nucleic acid oligomers from cyclic monomers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-01-20 | — | — | US | disclosed |
| US-20080038349-A1 | Peptide-Pna Chimera Targeting Inducible Nitric Oxide Synthetase | ITSCHAK LAMENSDORF | 2008-02-14 | — | — | US | disclosed |
| EP-1680438-A2 | AMIPHIPHYLIC PEPTIDE-PNA CONJUGATES FOR THE DELIVERY OF PNA THROUGH THE BLOOD BRAIN BARRIER | Kernel Biopharma Inc. (IL) | 2006-07-19 | — | — | EP | disclosed |
| EP-1680439-A2 | DUAL PHASE-PNA CONJUGATES FOR THE DELIVERY OF PNA THROUGH THE BLOOD BRAIN BARRIER | Kernel Biopharma Inc. (IL) | 2006-07-19 | — | — | EP | disclosed |
| WO-2002053574-A3 | MODIFIED PNA MOLECULES | PANTHECO AS (DK) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002042316-A3 | PNA ANALOGUES | PANTHECO AS (DK) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002053574-A2 | MODIFIED PNA MOLECULES | PANTHECO A/S (DK) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002042316-A2 | PNA ANALOGUES | PANTHECO A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002042316-A2 | PNA ANALOGUES | PANTHECO A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063906-A1 | Peptide nucleic acid sequences; antibodies for controlling disease; bactericides, viricides | LNPEP, VIP, BCDIN3D | DPP7 369/4885DPP4 302/4885DPP8 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.